IRX4204, a compound that Io Therapeutics is developing to treat neurological diseases, facilitated myelin repair and improved walking abilities in a mouse model of multiple sclerosis (MS) in a recent study, scientists report.
“Our findings support the therapeutic potential of IRX4204 to promote functional neurologic recovery in MS, a long-sought therapeutic objective in the MS research community,” George S. Robertson, PhD, a study co-author at Dalhousie University in Canada and lead scientist for this work, said in a company press release. Read full story HERE.